BS_0Y66ZBWE
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 68.46254927726675
- age_years
- 6.016
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.279
- BILE_ACID_METABOLISM+0.093
- PANCREAS_BETA_CELLS+0.039
- APICAL_SURFACE+0.001
- SPERMATOGENESIS-0.005
- HEDGEHOG_SIGNALING-0.013
- ESTROGEN_RESPONSE_EARLY-0.056
- NOTCH_SIGNALING-0.064
- UV_RESPONSE_DN-0.068
- MYOGENESIS-0.077
Top 10 suppressed
- MYC_TARGETS_V1-0.608
- E2F_TARGETS-0.537
- ANGIOGENESIS-0.524
- INTERFERON_ALPHA_RESPONSE-0.523
- INTERFERON_GAMMA_RESPONSE-0.518
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.516
- MYC_TARGETS_V2-0.507
- TNFA_SIGNALING_VIA_NFKB-0.506
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.499
- ALLOGRAFT_REJECTION-0.495
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3P20Q2C3 | low-grade glioma | — | 0.964 |
| 2 | BS_90B22NGP | ATRT | — | 0.951 |
| 3 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.949 |
| 4 | BS_52MPKTJH | high-grade glioma | — | 0.947 |
| 5 | C3N-02950 | — | cohortA1 | 0.944 |
| 6 | BS_FEPRNEXX | Embryonal tumors | — | 0.940 |
| 7 | SRR1478032 | GTEX | — | 0.939 |
| 8 | MNG491 | — | — | 0.935 |
| 9 | BS_0T17SY47 | low-grade glioma | — | 0.935 |
| 10 | SRR1334717 | GTEX | — | 0.932 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.279 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.093 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.039 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.001 | Temsirolimus | — uncovered |